Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;35(2):435-452.
doi: 10.1016/j.idc.2021.03.009.

Mucormycosis

Julie M Steinbrink  1 , Marisa H Miceli  2
Affiliations
Review

Mucormycosis

Julie M Steinbrink et al. Infect Dis Clin North Am. 2021 Jun.

Abstract

Mucormycosis is a rare but aggressive fungal disease that mainly affects patients with poorly controlled diabetes mellitus and those who are severely immunocompromised, including patients with hematological malignancies and solid organ transplant recipients. Early recognition of infection is critical for treatment success, followed by prompt initiation of antifungal therapy with lipid formulation amphotericin B. Posaconazole and isavuconazole should be used for stepdown and salvage therapy. Surgical debridement is key for tissue diagnosis and treatment and should be pursued urgently whenever possible. In addition to surgery and antifungal therapy, reverting the underlying risk factor for infection is important for treatment response.

Keywords: Diabetes mellitus; Immunocompromised host; Mucorales; Mucormycosis.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Structure of Rhizopus
Figure 2:
Figure 2:
Distinctive features of Mucorales vs. Aspergillus species
Figure 3:
Figure 3:
Skin lesion secondary to trauma in patient with cutaneous mucormycosis
Figure 4:
Figure 4:
Clinical course of localized cutaneous mucormycosis in patient with non-Hodgkin lymphoma
Figure 5:
Figure 5:
Reverse halo sign in patients with pulmonary mucormycosis
Figure 6:
Figure 6:
Radiological progression of pulmonary mucormycosis in a patient with relapsed acute leukemia and persistent neutropenia
See this image and copyright information in PMC

References

    1. Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev. 2011;24(2):411–445. - PMC - PubMed
    1. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13(2):236–301. - PMC - PubMed
    1. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–653. - PubMed
    1. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004;10 Suppl 1:31–47. - PubMed
    1. Lanternier F, Dannaoui E, Morizot G, et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005–2007). Clin Infect Dis. 2012;54 Suppl 1:S35–43. - PubMed

Publication types

MeSH terms

Substances